James Inglese, Ph.D., Investigator at National Center for Advancing Translational Sciences (NCATS)
Dr. Inglese currently heads a laboratory focused on the development of assay and screening technology targeting rare and neglected disease within the National Center for Advancing Translational Sciences (NCATS) and is an Adjunct Investigator of the National Human Genome Research Institute (NHGRI). Prior to this he co-founded the NIH Chemical Genomics Center (NCGC) acting as its Deputy Director.
Dr. Inglese received his Ph.D. in Organic Chemistry from the Pennsylvania State University and completed post-doctoral training in the laboratory of Prof. Robert J. Lefkowitz at Duke University Medical Center.
Before coming to the NIH, Dr. Inglese led research teams at the Princeton-based biotech Pharmacopeia and Merck Research Laboratories.
Over the past two decades, Dr. Inglese has contributed to over 150 publications and patents; his efforts on the early drug discovery process have resulted in novel assay formats and high throughput screening paradigms.
Dr. Inglese is the Founding Editor (2002) and Editor-in-Chief of the journal, ASSAY and Drug Development Technologies and serves on the scientific advisory boards of several NIH-funded chemistry and screening centers and international chemical biology consortia.